What to expect from JAK inhibitor therapy for alopecia totalis

Alopecia totalis involves loss of scalp hair across the scalp rather than a single small patch. JAK inhibitors target immune signalling that can interfere with follicle activity. The treatment goal is to support a return to the hair-growth cycle; it does not rebuild a scarred follicle. Early changes may be subtle, with soft or lightly coloured hairs appearing before thicker scalp hair. Eyebrow, eyelash, and body hair may respond differently from scalp hair.

Before prescribing, your dermatologist will consider previous treatments, other illnesses, medicines, infection history, and vaccination needs. Take the medicine exactly as directed and keep scheduled reviews and laboratory checks. Protect a hairless scalp from sun and cold with suitable clothing or sunscreen, and use gentle products on sensitive skin. Record changes in scalp, brows, lashes, and nails, because these details help your clinician judge the response.

Contact your treatment team promptly if you develop fever, a new persistent cough, painful sores, worsening redness, or other signs of infection. Seek urgent care for chest pain, severe shortness of breath, sudden one-sided weakness, or facial or throat swelling. Do not stop or restart the medicine on your own after an illness; ask the prescribing clinician for an individual plan.

Ask how alopecia totalis will be assessed, when early regrowth might be reviewed, which tests are needed, and how missed doses or infections should be handled. Ask whether the plan changes if eyebrows or eyelashes remain affected, and discuss pregnancy, vaccines, travel, and contact with people who are unwell.